Vaccine

On 5 May 2026, BioNTech announces: up to 1,860 jobs cut — 22 percent of its workforce. The plants in Idar-Oberstein and Marburg close by end of 2027. The CureVac sites too. COVID vaccine production transfers entirely to Pfizer.

Update April 3, 2026: Article expanded with Japanese PMDA approval documents: missing studies, S-protein detected in ovaries, post-marketing data from Japan. There is one critical difference between a conventional mRNA vaccine and what the EU approved in February 2025.